The Joint is Jumping: CGMS, AI and Wearables

Senseonics has taken their Eversense implantable CGM before an FDA panel, and Bigfoot has announced they have closed their series B $55 million financing round. The FDA has approved Dexcom's G6 system, pushing shares in the company higher in early trading. And while they didn't announce anything recently, our friends at Tandem are feeling the love as shares continue to surge higher in anticipation of their new system, which has low glucose suspend. Simply put, when it comes to diabetes devices, CGM and insulin pumps, the joint is jumping. But before everyone breaks into an unstoppable happy dance, I'd advise they slow their roll.